What You Should Know:
– Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse® wearable drug delivery platform and Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its POZ Platform™ to develop and improve efficacy and safety across multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs), today announced a partnership to develop and commercialize SER-252 (POZ-apomorphine) in combination with enFuse for the treatment of Parkinson’s disease.
– SER-252 is an investigational apomorphine therapy developed with Serina’s POZ platform and designed to provide continuous dopaminergic stimulation (CDS).
Serina Partners with Enable for Innovative Drug Delivery in Parkinson’s Disease
CDS has been shown to reduce the severity of levodopa-related motor complications, such as dyskinesia, in Parkinson’s disease. Preclinical studies indicate that SER-252 can provide CDS without causing skin reactions. Serina plans to begin clinical testing of SER-252 in 2025.
enFuse is an innovative, wearable drug delivery platform designed for subcutaneous administration of large medication volumes. This system allows patients to receive treatment via a simple injection under the skin, avoiding the need for intravenous delivery. enFuse addresses the limitations of IV infusions and other subcutaneous methods by offering fast, simple, and convenient delivery, enabling patient self-administration and benefiting patients, healthcare providers, and payers.
Enable is collaborating with several pharmaceutical partners to conduct clinical trials and plan for joint commercial launches of therapies using the enFuse technology. Enable is selectively expanding its pharmaceutical partnerships to include treatments and patient populations that will benefit from enFuse. The first enFuse combination product received U.S. Food and Drug Administration approval in 2023.
Under the agreement, Serina will receive a worldwide, exclusive license to the enFuse platform in exchange for upfront and milestone payments. Enable will also receive a share of product sales and single-digit royalties.
“Current apomorphine treatments require daily and time-consuming infusions through an electronic pump that not only burdens patients and providers, but can cause significant skin reactions,” said Randall Moreadith, M.D., Ph.D., Chief Development Officer of Serina Therapeutics. “With enFuse, patients can self-administer SER-252 in the convenience of their home with wearable technology and with a rapid treatment time. If effective, a SER-252 and enFuse combination provides the potential for patients to remain in a continuous ‘ON’ state and avoid dyskinesia.”
